Predicting SSRI Efficacy in Veterans With PTSD

第4相早期終了 NCT04183205

対象疾患	Posttraumatic Stress Disorder, Major Depressive Disorder
相	第4相
スポンサー	VA Office of Research and Development
ステータス	早期終了
参加者数	19 名
介入（薬剤）	LDAEP, sertraline
開始日	2019年9月11日
完了日	2025年3月30日
結果公開日	2026年5月22日

概要

This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the PZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm	10.8 ± 9.95 Scores on a scale

p-value	.08
Slope	3.13

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the CZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm	10.8 ± 9.95 Scores on a scale

p-value	.01
Slope	3.59

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the FZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm	10.8 ± 25.7 Scores on a scale

p-value	.24
Slope	2.24

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

CBT+ for Depression — University of Wisconsin, Madison
Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский